[go: up one dir, main page]

RU2019110128A3 - - Google Patents

Download PDF

Info

Publication number
RU2019110128A3
RU2019110128A3 RU2019110128A RU2019110128A RU2019110128A3 RU 2019110128 A3 RU2019110128 A3 RU 2019110128A3 RU 2019110128 A RU2019110128 A RU 2019110128A RU 2019110128 A RU2019110128 A RU 2019110128A RU 2019110128 A3 RU2019110128 A3 RU 2019110128A3
Authority
RU
Russia
Application number
RU2019110128A
Other versions
RU2019110128A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019110128A publication Critical patent/RU2019110128A/ru
Publication of RU2019110128A3 publication Critical patent/RU2019110128A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B02CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02CCRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019110128A 2012-02-28 2013-02-28 Ингаляционные фармацевтические композиции RU2019110128A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261604435P 2012-02-28 2012-02-28
US61/604,435 2012-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014139046A Division RU2697862C2 (ru) 2012-02-28 2013-02-28 Ингаляционные фармацевтические композиции

Publications (2)

Publication Number Publication Date
RU2019110128A RU2019110128A (ru) 2019-05-08
RU2019110128A3 true RU2019110128A3 (ru) 2020-06-04

Family

ID=48628732

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019110128A RU2019110128A (ru) 2012-02-28 2013-02-28 Ингаляционные фармацевтические композиции
RU2014139046A RU2697862C2 (ru) 2012-02-28 2013-02-28 Ингаляционные фармацевтические композиции

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014139046A RU2697862C2 (ru) 2012-02-28 2013-02-28 Ингаляционные фармацевтические композиции

Country Status (14)

Country Link
US (2) US10022303B2 (ru)
EP (1) EP2819645A2 (ru)
JP (1) JP6231022B2 (ru)
KR (2) KR20200015828A (ru)
CN (2) CN104703584B (ru)
AU (3) AU2013227351B2 (ru)
CA (1) CA2865702C (ru)
HK (1) HK1252926A1 (ru)
IL (1) IL234365B (ru)
NZ (2) NZ722952A (ru)
RU (2) RU2019110128A (ru)
SG (2) SG11201405243TA (ru)
WO (1) WO2013128283A2 (ru)
ZA (1) ZA201703992B (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4400921A3 (en) 2012-06-25 2024-10-09 Gecko Health Innovations, Inc. Devices, systems, and methods for adherence monitoring and patient interaction
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
AU2014312428B2 (en) 2013-08-28 2018-10-11 Gecko Health Innovations, Inc. Devices, systems, and methods for adherence monitoring and devices, systems, and methods for monitoring use of consumable dispensers
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
DK3107548T3 (da) 2014-02-20 2022-07-18 Otitopic Inc Tørpulverformuleringer til inhalation
CN105828819A (zh) * 2014-04-08 2016-08-03 桑萨(巴巴多斯)公司 烟碱制剂及其制备方法
EP3151856B1 (en) * 2014-06-06 2019-08-07 Merck Patent GmbH Antigen-loaded chitosan nanoparticles for immunotherapy
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
WO2015191558A1 (en) 2014-06-09 2015-12-17 Biometry Inc. Low cost test strip and method to measure analyte
KR102666667B1 (ko) * 2014-07-31 2024-05-17 벡추라 인코포레이티드 흡입용 건조 분말 제형
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
WO2016176552A1 (en) 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
US11723864B2 (en) 2015-05-29 2023-08-15 The Texas A&M University System Antimicrobial and anti-inflammatory compositions
AU2016287453A1 (en) * 2015-06-30 2017-09-28 Société des Produits Nestlé S.A. Composition suitable for protecting microorganisms
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
KR101880295B1 (ko) * 2016-01-12 2018-08-02 주식회사 시너지이노베이션 디히드로에르고타민 타트레이트를 포함하는 폐암의 예방 또는 치료용 조성물
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
CA3031247A1 (en) 2016-07-19 2018-01-25 Biometry Inc. Methods of and systems for measuring analytes using batch calibratable test strips
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
WO2018047002A1 (en) 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
WO2018047013A1 (en) 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US10786456B2 (en) * 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN115919780A (zh) * 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
KR20200117998A (ko) * 2018-02-01 2020-10-14 코버스 파마슈티칼스, 인크. 약학적 조성물
CA3211506A1 (en) 2018-02-07 2019-08-15 Lovelace Biomedical Research Institute Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
EP3762104A2 (en) 2018-03-07 2021-01-13 ST IP Holding AG Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
IT201800006909A1 (it) * 2018-07-04 2020-01-04 Polvere secca di ambroxolo per uso inalatorio con target bronchiale
EP3910324A1 (en) 2018-08-07 2021-11-17 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
CN113694068A (zh) 2018-09-18 2021-11-26 St知识产权控股公司 4-烷基-5-杂芳基-3h-1,2-二硫杂环戊烯-3-硫酮的旋转异构异构体
GB2578093B (en) * 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
EP3673895A1 (en) * 2018-12-28 2020-07-01 Université Libre de Bruxelles Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
US11499904B2 (en) * 2020-02-12 2022-11-15 National Guard Health Affairs In vitro dissolution test method for fluticasone propionate and other inhaled drugs
WO2021186244A1 (en) 2020-03-16 2021-09-23 St Ip Holding Ag Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2-dithiole-3-thiones
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
IL300652A (en) 2020-08-14 2023-04-01 Norton Waterford Ltd Inhalable formulation of fluticasone propionate and albuterol sulfate
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法
KR102488719B1 (ko) * 2020-12-03 2023-01-13 충북대학교 산학협력단 셀레시파그를 함유하는 건조 분말 흡입 제제 및 그 제조방법
KR20230039894A (ko) * 2021-09-14 2023-03-22 한국유나이티드제약 주식회사 코로나 19 바이러스 감염 질환의 예방 또는 치료를 위한 흡입형 약학조성물
WO2023105086A1 (en) * 2021-12-10 2023-06-15 Gudiminchi Rama Krishna Use of glycosylated sugar alcohols
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
JP2025520674A (ja) * 2022-06-21 2025-07-03 ホビオネ サイエンティア リミテッド 糖及び脂質複合粒子を含む吸入用結晶性医薬組成物及び製造方法
WO2024009079A1 (en) 2022-07-04 2024-01-11 Hovione Scientia Limited Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
KR20250112022A (ko) * 2024-01-16 2025-07-23 피투케이바이오 주식회사 리바록사반 흡입용 조성물
CN120549895B (zh) * 2025-05-24 2025-11-25 上海华茂药业有限公司 一种基于筛分乳糖的可吸入粉末制剂及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1084994B (it) * 1976-06-09 1985-05-28 Funk Heporaut Kirsti Guarnizione per alberi,in particolare in mulini con agiotatore oppure in mulini colloidali
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
HUP0101608A2 (hu) * 1998-04-18 2002-03-28 Glaxo Group Limited Aeroszol formájú gyógyszerkészítmény és eljárás előállítására
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
WO2002017883A2 (en) * 2000-08-31 2002-03-07 Rtp Pharma Inc. Milled particles
DK1337240T4 (en) * 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
AU2002330390A1 (en) * 2002-03-20 2003-09-29 Hosokawa Micron Corporation Method of manufacturing chemical-containing composite particles
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005072702A2 (en) * 2004-01-20 2005-08-11 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
US8900555B2 (en) 2006-07-27 2014-12-02 Nektar Therapeutics Insulin derivative formulations for pulmonary delivery
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
PT2410981T (pt) 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
AU2009100698B4 (en) * 2009-07-17 2010-04-15 Astrazeneca Ab Combination
CA2784207C (en) * 2009-12-14 2018-06-05 Chiesi Farmaceutici S.P.A. Antibiotic microparticles for inhalation

Also Published As

Publication number Publication date
CN104703584B (zh) 2019-05-31
US20140065219A1 (en) 2014-03-06
CA2865702C (en) 2020-04-28
US20180318170A1 (en) 2018-11-08
CN107875127A (zh) 2018-04-06
SG11201405243TA (en) 2014-09-26
NZ629438A (en) 2016-10-28
ZA201703992B (en) 2019-12-18
EP2819645A2 (en) 2015-01-07
NZ722952A (en) 2018-12-21
IL234365B (en) 2019-09-26
AU2016202881A1 (en) 2016-05-26
AU2017213466A1 (en) 2017-08-31
HK1210706A1 (en) 2016-05-06
CA2865702A1 (en) 2013-09-06
KR20200015828A (ko) 2020-02-12
RU2019110128A (ru) 2019-05-08
JP2015508808A (ja) 2015-03-23
WO2013128283A2 (en) 2013-09-06
KR20150041608A (ko) 2015-04-16
RU2697862C2 (ru) 2019-08-21
HK1252926A1 (zh) 2019-06-06
AU2013227351B2 (en) 2016-06-16
AU2013227351A1 (en) 2014-09-18
WO2013128283A3 (en) 2013-10-31
AU2017213466B2 (en) 2019-03-14
RU2014139046A (ru) 2016-04-20
CN104703584A (zh) 2015-06-10
US10022303B2 (en) 2018-07-17
JP6231022B2 (ja) 2017-11-15
SG10201703243QA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
BR112014017635A2 (ru)
BR112014017614A2 (ru)
RU2019110128A3 (ru)
BR112014017625A2 (ru)
BR112014017659A2 (ru)
BR112014017592A2 (ru)
BR112014017646A2 (ru)
BR112014017607A2 (ru)
BR112014017638A2 (ru)
AR092201A1 (ru)
BR112014018773A2 (ru)
BR112013027865A2 (ru)
BR112014017609A2 (ru)
BR112014017634A2 (ru)
BR112014017644A2 (ru)
BR112014017588A2 (ru)
BR112014017618A2 (ru)
BR112014017647A2 (ru)
BR112014013184A8 (ru)
BR112014017623A2 (ru)
BR112014017652A2 (ru)
BR112014017630A2 (ru)
BR112014017627A2 (ru)
BR112014017621A2 (ru)
BR112014017631A2 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20201026